Pulmonary administration of granulocyte colony stimulating factor
Patent 5284656 Issued on February 8, 1994. Estimated Expiration Date: 
September 29, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
September 29, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesNovel CSF and method for obtaining the same Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor Method of treating infectious diseases with granulocyte colony-stimulating factor Patent #: 5043156 InventorsApplicationNo. 953208 filed on 09/29/1992US Classes:424/435, Mouth424/43, EFFERVESCENT OR PRESSURIZED FLUID CONTAINING424/46, Powder or dust containing424/85.1, LYMPHOKINE424/434, Mucosal (e.g., nasal, etc.)514/2, Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI514/8, Glycoprotein (carbohydrate containing)514/21, Produced by or extracted from animal tissue514/885, IMMUNE RESPONSE AFFECTING DRUG514/951, POWDERS, GRANULES OR PARTICLES OF SPECIFIED MESH OR PARTICLE SIZE530/350, PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES530/395, Glycoprotein, e.g., mucins proteoglycans, etc.530/397, Glycoprotein hormones530/838Marrow; spleenExaminersPrimary: Page, Thurman K.Assistant: Azpuru, Carlos Attorney, Agent or FirmInternational ClassesA61K 009/14A61K 045/05 C07K 017/10 C07K 015/14 AbstractGranulocyte-colony stimulating factor (G-CSF) can be delivered systemically in therapeutically or prophylactically effective amounts by pulmonary administration using a variety of pulmonary delivery devices, including nebulizers, metered dose inhalers and powder inhalers. Aerosol administration in accordance with this invention results in significant elevation of the neutrophil levels that compares favorably with delivery by subcutaneous injection. G-CSF can be administered in this manner to medically treat neutropenia, as well as to combat or prevent infections.Field of SearchEFFERVESCENT OR PRESSURIZED FLUID CONTAININGPowder or dust containing LYMPHOKINE Mucosal (e.g., nasal, etc.) Mouth Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI Glycoprotein (carbohydrate containing) Produced by or extracted from animal tissue IMMUNE RESPONSE AFFECTING DRUG PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES Glycoprotein, e.g., mucins proteoglycans, etc. Glycoprotein hormones Marrow; spleen |
| ||||||||||||||
